Mounting evidence suggests safety and efficacy of psychedelic compounds as potential
novel therapeutics in psychiatry. Ketamine has been approved by the Food and Drug …

We present a comprehensive overview of the neurobiology of unipolar major depression
and antidepressant drug action, integrating data from affective neuroscience, neuro-and …

Comorbid depression and chronic pain are highly prevalent in individuals suffering from
physical illness. Here, we critically examine the possibility that inflammation is the common …

Exposure to stressful events can be differently perceived by individuals and can have
persistent sequelae depending on the level of stress resilience or vulnerability of each …

Ketamine, a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptor, displays
a fast antidepressant activity in treatment-resistant depression and in rodent models of …

Acute pain induces depressed mood, and chronic pain is known to cause depression.
Depression, meanwhile, can also adversely affect pain behaviors ranging from …

Depression is a common cause of mortality and morbidity, but the biological bases of the
deficits in emotional and cognitive processing remain incompletely understood. Current …

It is well accepted that events that interfere with the normal program of neuronal
differentiation and brain maturation may be relevant for the etiology of psychiatric disorders …

Major depressive disorder (MDD) is a common, chronic, recurrent mental illness that affects
millions of individuals worldwide. To date, the monoaminergic systems (serotonin …

Major depressive disorder (MDD) is a severe, debilitating medical illness that affects millions
of individuals worldwide. The young age of onset and chronicity of the disorder has a …